Phase I Clinical Protocol of BCG-PPD in Healthy People
Phase 1
Completed
- Conditions
- Tuberculosis
- Interventions
- Drug: BCG-PPD
- First Posted Date
- 2020-10-20
- Last Posted Date
- 2022-02-22
- Lead Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT04593771
- Locations
- 🇨🇳
Sichuan Center for Disease Control and Prevention, Chendu, Sichuan, China
Clinical Trial of Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris)
Phase 1
Completed
- Conditions
- Acute Gastroenteritis
- Interventions
- Biological: Low-dose vaccineBiological: High-dose vaccineBiological: Placebo (containing aluminum)Biological: Placebo (without aluminum)
- First Posted Date
- 2020-09-24
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- Target Recruit Count
- 580
- Registration Number
- NCT04563533
- Locations
- 🇨🇳
Liuzhou Center for Disease Control and Prevention, Liuzhou, Guangxi, China
Clinical Study of BCG Vaccine for Intradermal Injection
Phase 1
Completed
- Conditions
- Tuberculosis
- Interventions
- Biological: BCG vaccine 1（0.025mg/0.1ml/person）Biological: BCG vaccine 2 （0.05mg/0.1ml/person）Biological: BCG vaccine 3（0.075mg/0.1ml/person）Biological: BCG vaccine 4 （0.075mg/0.1ml/person）Biological: Placebo of BCG vaccine （0.1ml/person）
- First Posted Date
- 2020-09-24
- Last Posted Date
- 2023-05-09
- Lead Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- Target Recruit Count
- 160
- Registration Number
- NCT04563273
- Locations
- 🇨🇳
Sichuan Center for Disease Control and Prevention, Chendu, Sichuan, China
Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2 Phase I Clinical Trial (≥60 Years Old)
Phase 1
- Conditions
- Coronavirus
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2021-01-27
- Lead Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT04550351
- Locations
- 🇨🇳
Hunan Provincial Center for Disease Control and Prevention, Xiangtan, Changsha, China
Phase I Clinical Protocol for Pre-evaluation of the Safety of BCG-PPD in Tuberculosis Patients
Phase 1
Active, not recruiting
- Conditions
- Tuberculosis
- Interventions
- Drug: BCG-PPD
- First Posted Date
- 2020-09-04
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT04538911
- Locations
- 🇨🇳
The Third People's Hospital Of Shenzhen, Shenzhen, Guangdong, China
Clinical Study of Recombinant Novel Coronavirus Vaccine
Phase 2
- Conditions
- Coronavirus
- Interventions
- Biological: Recombinant new coronavirus vaccine (CHO cells) high-dose groupBiological: Recombinant new coronavirus vaccine (CHO cells) placebo groupBiological: Recombinant new coronavirus vaccine (CHO cell) low-dose group
- First Posted Date
- 2020-07-10
- Last Posted Date
- 2020-12-03
- Lead Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- Target Recruit Count
- 900
- Registration Number
- NCT04466085
- Locations
- 🇨🇳
Hunan Provincial Center for Disease Control and Prevention, Hunan, Changsha, China
Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine
Phase 1
- Conditions
- Coronavirus
- Interventions
- Biological: Recombinant new coronavirus vaccine (CHO cell) low-dose groupBiological: Recombinant new coronavirus vaccine (CHO cells) placebo groupBiological: Recombinant new coronavirus vaccine (CHO cells) high-dose group
- First Posted Date
- 2020-06-24
- Last Posted Date
- 2020-12-03
- Lead Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT04445194
- Locations
- 🇨🇳
The Second Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China
A Phase Ib Study of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried (AEC/BC02)
Phase 1
Completed
- Conditions
- Tuberculosis
- Interventions
- Biological: Low-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02)Biological: Lyophilized recombinant tuberculosis vaccine (AEC / BC02) placeboBiological: Low-dose adjuvant for freeze-dried recombinant tuberculosis vaccine (AEC / BC02)
- First Posted Date
- 2020-01-27
- Last Posted Date
- 2022-09-06
- Lead Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT04239313
- Locations
- 🇨🇳
Wuhan Infectious Disease Hospital, Wuhan, Hubei, China
Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT6-CFP10 Allergen for Children
Phase 3
Completed
- Conditions
- Tuberculosis Diagnosis
- Interventions
- Biological: ESAT6-CFP10 in left arm and TB-PPD in right armBiological: ESAT6-CFP10 in right arm and TB-PPD in left arm
- First Posted Date
- 2017-01-23
- Last Posted Date
- 2018-04-12
- Lead Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- Target Recruit Count
- 96
- Registration Number
- NCT03027154
- Locations
- 🇨🇳
Wuhan Medical Treatment Center, Wuhan, Hubei, China
🇨🇳Beijing Children's Hospital, Beijing, China
🇨🇳Shanghai Public Health Clinical Center, Shanghai, China
A Phase ⅠStudy of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried
Phase 1
Completed
- Conditions
- Tuberculosis
- Interventions
- Biological: PlaceboBiological: High dose adjuvantBiological: Low dose adjuvantBiological: Low dose vaccineBiological: High dose vaccine
- First Posted Date
- 2017-01-20
- Last Posted Date
- 2022-03-24
- Lead Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- Target Recruit Count
- 25
- Registration Number
- NCT03026972
- Locations
- 🇨🇳
Shanghai Public Health clinical Center, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath